Looking for the value option

4 January 2007 By John Foley

The Dutch conglomerate is pushing on with a float of the pharma business. That means investors have to take a punt on the drug pipeline. But the operation s health has deteriorated. At the right price, a bid could prove the more attractive option for shareholders.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)